As U.S. stock indexes experience a downturn ahead of crucial inflation data, investors are keenly observing economic indicators and market dynamics. In such a climate, penny stocks—often representing smaller or emerging companies—remain an intriguing investment area despite the term's outdated connotations. These stocks can offer unique growth opportunities when they are supported by strong financial health and solid fundamentals, potentially providing returns that defy typical expectations in a challenging market landscape.
Top 10 Penny Stocks In The United States
| Name | Share Price | Market Cap | Rewards & Risks |
| Dingdong (Cayman) (DDL) | $2.10 | $447.9M | ✅ 4 ⚠️ 0 View Analysis > |
| Waterdrop (WDH) | $1.99 | $705.24M | ✅ 4 ⚠️ 0 View Analysis > |
| Global Self Storage (SELF) | $5.00 | $56.92M | ✅ 5 ⚠️ 1 View Analysis > |
| Puma Biotechnology (PBYI) | $4.70 | $237.75M | ✅ 3 ⚠️ 2 View Analysis > |
| Sensus Healthcare (SRTS) | $3.13 | $51.95M | ✅ 4 ⚠️ 2 View Analysis > |
| Performance Shipping (PSHG) | $1.99 | $25.49M | ✅ 4 ⚠️ 2 View Analysis > |
| Golden Growers Cooperative (GGRO.U) | $5.00 | $77.45M | ✅ 2 ⚠️ 5 View Analysis > |
| Table Trac (TBTC) | $4.50 | $21.81M | ✅ 2 ⚠️ 2 View Analysis > |
| BAB (BABB) | $0.9962 | $7.26M | ✅ 2 ⚠️ 3 View Analysis > |
| Lifetime Brands (LCUT) | $3.77 | $87M | ✅ 3 ⚠️ 2 View Analysis > |
Click here to see the full list of 375 stocks from our US Penny Stocks screener.
Let's review some notable picks from our screened stocks.
Ovid Therapeutics (OVID)
Simply Wall St Financial Health Rating: ★★★★☆☆
Overview: Ovid Therapeutics Inc. is a biopharmaceutical company focused on developing impactful medicines for epilepsies and seizure-related neurological disorders in the United States, with a market cap of $99.55 million.
Operations: The company generates revenue of $6.65 million from its pharmaceuticals segment.
Market Cap: $99.55M
Ovid Therapeutics, a biopharmaceutical company, has seen its revenue grow to US$6.65 million, yet it remains unprofitable with increasing losses. Despite having no debt and experienced management, the company's cash runway is less than a year if current free cash flow trends persist. Recent earnings reports show significant revenue growth but also increased net losses compared to last year. The stock is highly volatile and not expected to achieve profitability in the next three years. A reverse stock split has been approved by the board, potentially impacting share liquidity and market perception moving forward.
- Dive into the specifics of Ovid Therapeutics here with our thorough balance sheet health report.
- Review our growth performance report to gain insights into Ovid Therapeutics' future.
Zevia PBC (ZVIA)
Simply Wall St Financial Health Rating: ★★★★★☆
Overview: Zevia PBC develops, markets, sells, and distributes zero sugar beverages in the United States and Canada, with a market cap of $188.87 million.
Operations: The company's revenue is generated from its non-alcoholic beverages segment, which amounts to $158.37 million.
Market Cap: $188.87M
Zevia PBC, with a market cap of US$188.87 million, has maintained a strong cash position, sufficient for over three years based on current free cash flow. Despite being unprofitable with a negative return on equity and no forecasted profitability in the next three years, the company has reduced its losses over the past five years. Recent earnings showed sales growth to US$44.52 million for Q2 2025, while net losses decreased significantly compared to last year. Zevia's shares have not been meaningfully diluted recently and are trading below estimated fair value relative to peers and industry standards.
- Navigate through the intricacies of Zevia PBC with our comprehensive balance sheet health report here.
- Evaluate Zevia PBC's prospects by accessing our earnings growth report.
Taking Advantage
- Click this link to deep-dive into the 375 companies within our US Penny Stocks screener.
- Ready For A Different Approach? We've found 19 US stocks that are forecast to pay a dividend yeild of over 6% next year. See the full list for free.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Valuation is complex, but we're here to simplify it.
Discover if Zevia PBC might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com